Research & Development
Pancreatic Cancer: Page 2
How to manage genetic testing of pancreatic cancer patients
The National Comprehensive Cancer Network recently recommended germline testing for all people newly diagnosed with pancreatic ductal adenocarcinoma (PDAC). Also, the American Society of Clinical Oncology has issued a clinical opinion advising risk assessment and consideration of germline testing for all patients newly diagnosed, Dr. Eileen O'Reilly, an oncologist at Memorial Sloan Kettering Cancer Center, and colleagues observed. But opinions on what, exactly, to test for have been divided, and guidance has been lacking, they suggested in JAMA Oncology.
February 13, 2020
Top 10 stories for 2019 | Pancreatic cancer mutations | Is genetic testing up to scratch?
Dear LabPulse Member,
January 6, 2020
Lynparza PARP approval opens door to more pancreatic cancer testing
The targeted poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza was approved as a first-line maintenance treatment for germline BRCA-mutated metastatic pancreatic cancer, Merck and AstraZeneca announced on December 30. The "maintenance" approval covers those who respond to platinum-based chemotherapy and have not progressed. On the same day, Myriad Genetics announced the FDA approval of its BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza.
January 1, 2020
Bluestar bolsters blood test with breast, pancreatic cancer data
The company has developed a platform for genome-wide profiling of the biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA), which it hopes to apply across multiple cancers.
September 16, 2019
Invitae provides free testing to pancreatic cancer patients
Patients must meet criteria in specific clinical areas where genetic testing is underutilized to be eligible for testing. Professional guidelines recommend genetic testing for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials, the company noted in a statement.
September 8, 2019
Thrive lifts off with multicancer liquid biopsy test
Developed by Johns Hopkins University researchers and licensed exclusively to Thrive, CancerSEEK tests DNA and protein in the blood and is designed for use in primary care settings. The test has breakthrough device designation with the U.S. Food and Drug Administration for use in detecting proteins and mutations associated with ovarian and pancreatic cancers.
May 29, 2019
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Page 2 of 2